Sattva Neelapu

Jan 8, 2025 | onclive.com | Sattva Neelapu

CommentaryVideoJanuary 8, 2025Author(s):Sattva S. Neelapu, MD, discusses a 5-year follow-up data for axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma. “These results indicate that axi-cel continues to be a highly effective therapeutic approach for patients with relapsed/refractory indolent lymphoma with the long-term durability of these responses observed at 5 years, [along with] long-term survival.”Sattva S.

Jul 4, 2024 | nature.com | Sang T. Kim |Sattva Neelapu |Amishi Y. Shah |Matthew Campbell |don gibbons |Tina Cascone | +10 more

Correction to: Nature Communications https://doi.org/10.1038/s41467-022-29539-3, published online 12 April 2022In this article the funding information for Jordan Kramer was omitted and should have read, ‘J.K. is supported by the CPRIT Research Training Award CPRIT Training Program (RP210028)’. The original article has been corrected.

Jun 12, 2024 | onclive.com | Sattva Neelapu

CommentaryVideoJune 12, 2024Author(s):Sattva S. Neelapu, MD, discusses processes that have been adopted to streamline the delivery of CAR T-cell therapy to patients with lymphoma. Sattva S.

Jun 11, 2024 | onclive.com | Sattva Neelapu

CommentaryVideoJune 11, 2024Author(s):Sattva S. Neelapu, MD, discusses key clinical trial data that support the use of CAR T-cell therapy in standard practice for patients with lymphoma. Sattva S. Neelapu, MD, deputy department chair, professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses key clinical trial data that support the use of CAR T-cell therapy in standard practice for patients with lymphoma.

May 21, 2024 | onclive.com | Sattva Neelapu

Sattva S. Neelapu, MD, deputy department chair, professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses mechanisms of resistance to CAR T-cell therapies in lymphoma and how CAR T-cell resistance may be addressed. One of the main reasons patients with lymphoma experience relapse after receiving CD19-directed CAR T-cell therapy is the loss of CD19 expression in the tumor at the time of progression, Neelapu begins.